Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndrome
Max Augustin(University of Cologne), Clara Lehmann(University of Cologne), Stella Ullrich(University of Cologne), Lea K. Picard(University of Cologne), Alexander Zoufaly, Elisabeth Pracht(University of Cologne), Philipp Schommers(University of Cologne), Jan Rybniker(University of Cologne), Maike Schlotz(University of Cologne), Ute Sandaradura de Silva(University of Cologne), Alexander Simonis(University of Cologne), Christoph Wenisch, Sebastian J. Theobald(University of Cologne), Gerd Fätkenheuer(University of Cologne), Ferdinand Heyn(University of Cologne), Michael Hallek(University of Cologne), Marie‐Christine Albert(University of Cologne), Isabelle Suárez(University of Cologne), Henning Walczak(University of Cologne), Florian Klein(University of Cologne), Viktoria Linne(University of Cologne), Carola Horn(University of Cologne), Henning Gruell(University of Cologne)
Cited by 12
Related Papers
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by <i>Staphylococcus aureus</i>
|New England Journal of Medicine|2006|1.5k